High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager CR, Boda A, Rajapakshe K, Lea ST, Di Francesco ME, Jayaprakash P, Slay RB, Morrow B, Prasad R, Dean MA, Duffy CR, Coarfa C, Jones P, Curran MA.
Ager CR, et al. Among authors: duffy cr.
J Immunother Cancer. 2021 Aug;9(8):e003246. doi: 10.1136/jitc-2021-003246.
J Immunother Cancer. 2021.
PMID: 34341132
Free PMC article.